LL37-rIb-AMP4 Hybrid Peptide as a Therapy for Systematic Infections of Acinetobacter baumannii, Pseudomonas aeruginosa, Vancomycin-resistant Enterococcus (VRE), and Methicillin-resistant Staphylococcus aureus (MRSA) cells in a mouse model. | ||
| Infection Epidemiology and Microbiology | ||
| Article 1, Volume 9, Issue 4, 2023, Pages 277-286 PDF (543.88 K) | ||
| Document Type: Original Research | ||
| DOI: 10.61186/iem.9.4.277 | ||
| Authors | ||
| shabnam Sadoogh Abbasian1; Ali Sadoogh Abbasian2; Ehsanollah Ghaznavi-Rad1; Ehsan Zarei-Mehrvarz1; Samira Sadelaji1; Hamid Abtahi* 1 | ||
| 1Molecular and Medical Research Center, Arak University of Medical Sciences, Arak, Iran. | ||
| 2Department of Internal Medicine, School of Medicine, Amiralmomenin Hospital, Arak University of Medical Sciences, Arak, Iran. | ||
| Abstract | ||
| Aims: Antimicrobial peptides (AMPs) are beneficial compounds that could be used as a new and effective method to suppress microbes. Both Ib-AMP4 and LL37 are antimicrobial peptides with a wide range of antimicrobial activities. This research aimed to evaluate the antibacterial potential of LL37-rIb-AMP4 hybrid protein as an antimicrobial agent against pathogenic bacteria. Therefore, its antibacterial effects against Acinetobacter baumannii, Pseudomonas aeruginosa, vancomycin-resistant Enterococcus (VRE), and methicillin-resistant Staphylococcus aureus (MRSA) were investigated in vivo and in vitro. Materials & Methods: In this study, antimicrobial peptides rIb-AMP4, LL37, and LL37-rIb-AMP4 were expressed, purified, and refolded, and their synergistic and antibacterial effects in combination with each other (LL37+rIb-AMP4) and as fusion proteins (LL37-rIb-AMP4) were tested against A. baumannii, P. aeruginosa, VRE, and MRSA cells in vitro (MIC, time kill, and SEM) and against P. aeruginosa and VRE cells in vivo. Findings: LL37-rIb-AMP4 Protein with molecular weight= 28 KD was correctly produced and purified. Despite the lack of synergistic effects between LL37 and rIb-AMP4 peptides in vitro, the stability test results showed higher stability for LL37-rIb-AMP4 hybrid protein. The findings of in vivo tests confirmed that all infected mice were improved with LL37-rIb-AMP4 and no signs of bacteria were observed in their blood and spleen samples. Also, these results confirmed the stability and higher activity of LL37-rIb-AMP4 than the single form of these proteins. Conclusion: Considering the antimicrobial potential of the produced proteins, it seems that the recombinant LL37-rIb-AMP4 protein could be considered and used as a stable and active antimicrobial drug in future studies. | ||
| Keywords | ||
| Antimicrobial peptides; Hybrid protein; LL37 peptide; rIb-AMP4 peptide | ||
| References | ||
|
| ||
|
Statistics Article View: 123 PDF Download: 68 |
||
| Number of Journals | 45 |
| Number of Issues | 2,171 |
| Number of Articles | 24,674 |
| Article View | 24,451,813 |
| PDF Download | 17,556,859 |